LGVN earnings

On track for August 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome, a rare pediatric disease and orphan-designated indicationClosed a private placement of up to $30 million, with $15 million funded in the initial closing, led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsCompany to host conference call and webcast today at 4:30 p.m. ET MIAMI, May 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic agi

MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report 2026 first quarter financial results and provide a business update on Wednesday, May 13, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details: Conference Call Number:1.877.407.0789Conference ID:13759888  Call me™ Feature:Click HereWebcast:Click Here   An archived replay of the webcast will be available on the "Events & Presentations" se

Issued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB:AVAI), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics, Inc. (NASDAQ:VKTX), Longeveron Inc. (NASDAQ:LGVN). Key Takeaways: The global anti-aging market generated more than $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science more than doubling to $8.49 billion across 325 deals last year.The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025 — including what researchers are calling the first drug class of "longevity therapeutics" — while big pharma spent more than $65 billion acquiring bi

On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS II may serve as foundation for a Biologics License Application (BLA) submission for full approval for HLHS, if results demonstrate sufficient evidence of efficacyClosed a private placement of up to $30 million, with $15 million funded in the initial closing, led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsCompany to host conference call and webcast today at 4:30 p.m. ET MIAMI, March 17

MIAMI, March 12, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report 2025 full year financial results and provide a business update on Tuesday, March 17, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details: Conference Call Number:1.877.407.0789Conference ID:13758462  Call meTM Feature:Click HereWebcast:Click Here   An archived replay of the webcast will be available on the "Events & Presentations" sec

MIAMI, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report third quarter 2025 financial results and provide a business update on Tuesday, November 4, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details:   Conference Call Number: 1.877.407.0789Conference ID: 13755997   Call me™ Feature: Click HereWebcast: Click Here An archived replay of the webcast will be available on the "Events & Presenta

MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report second quarter 2025 financial results and provide a business update on Wednesday, August 13, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details:  Conference Call Number:1.877.407.0789Conference ID:13754295  Call meTM Feature:Click HereWebcast:Click Here   An archived replay of the webcast will be available on t

Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to complete enrollment in the second quarter of 2025Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in 2026, if ELPIS II is successfulResults from the Phase 2a clinical trial (CLEAR MIND) evaluating laromestrocel as a potential treatment for Alzheimer's disease were published in Nature MedicinePositive FDA meeting regarding development pathway for laromestrocel in mild Alzheimer's disease; single, pivotal Phase 2/3 adaptive design clinica

MIAMI, May 02, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report first quarter 2025 financial results and provide a business update on Thursday, May 8, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details:      Conference Call Number:    1.877.407.0789 Conference ID:    13752361     Call meTM Feature:  Click HereWebcast:  Click Here     An archived replay of the webcast will be available o

Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more than 90% enrollment and is expected to complete enrollment in the second quarter of 2025Lomecel-B™ Biological License Application (BLA) submission for full traditional approval anticipated in 2026, if ELPIS II is successfulFDA meeting anticipated late in first quarter of 2025 to discuss possible development paths for Lomecel-B™ in mild Alzheimer's diseaseWHO International Nonproprietary Names (INN) Expert Committee approved "laromestrocel" for the non-proprietary name of Lomecel-B™Total Revenue

MIAMI, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report full-year 2024 financial results and provide a business update on Friday, February 28, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details: Conference Call Number:1.877.407.0789Conference ID:13751432  Call meTM Feature:Click HereWebcast:Click Here   An archived replay of the webcast will be available on

MIAMI, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report third quarter 2024 financial results and provide a business update on Tuesday, November 12, 2024 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call Details: Conference Call Number:1.877.407.0789Conference ID:13749428  Call me™ Feature:Click HereWebcast:Click Here   An archived replay of the webcast will be available on the "Events & Presentations" se

MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report second quarter 2024 financial results and provide a business update on Wednesday, August 14, 2024 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call Details:  Conference Call Number:1.877.407.0789Conference ID:13747923Call me™ Feature:Click HereWebcast:Click Here   An archived replay of the webcast will be available on the "Events & Presentations" sec

Phase 2b clinical trial evaluating Lomecel-BTM in rare pediatric disease HLHS on track for completing enrollment by end of 2024Data from Phase 2a clinical trial evaluating Lomecel-BTM in Alzheimer's Disease selected for Featured Research Oral Presentation at 2024 Alzheimer's Association International ConferenceCompleted two financings in April raising gross proceeds of $11.4 million to fund continued clinical developmentFocused expenditure management reduced first quarter Total Operating Expenses 8% year-over-yearCompany to host conference call and webcast today at 5:00pm ET MIAMI, May 14, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medi

MIAMI, May 02, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will report first quarter 2024 financial results and provide a business update on Tuesday, May 14, 2024 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 5:00 p.m. ET. Conference Call Details:    Conference Call Number:  1.877.407.0789    Conference ID:  13745868    Call meTM Feature:  Click Here    Webcast:  Click Here An archived replay of the webcast will be available on the "Events & Presentations" section of the Company's website following the co

Company Announces 2024 Strategic Priorities Focused on Advancement of Lomecel-B™ in Hypoplastic Left Heart Syndrome ELPIS II Phase 2 Trial of Lomecel-B™ in HLHS Continues Enrollment; Completion of Study Enrollment Anticipated in 2024 Long-term Survival Data from ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association Announced Additional Validating Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer's Disease Gross Proceeds of $6.4 Million in Equity Financing Secured in Q4 Registered Direct Offerings Company to Hold Conference Call and Webcast Today, February 27, 2023

MIAMI, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today that it will report its 2023 financial results after the market close on February 27, 2024. The Company will host a conference call at 5:00 p.m. ET that day to discuss the Company's results and provide a business update. TitleLongeveron Full Year 2023 Results Conference CallDate2/27/2024Time5 PM Eastern TimeConference Call Details1-877-407-0789Conference ID13744350Call meTM FeatureClick HereWebcastClick Here About Longeveron Inc. Longeveron is a clinical stage biotechnology comp

MIAMI, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today that it will report its third quarter 2023 financial results prior to the market open on Friday November 10, 2023. The Company will host a conference call and webcast that day to discuss the results, and provide an update on its clinical programs and corporate activities. A question-and-answer session will follow the prepared remarks. TitleLongeveron Third Quarter 2023 Financial ResultsDateFriday, November 10, 2023Time8:00 AM Eastern TimeConference

Company to Hold Conference Call & Webcast Today, October 5 at 8:00am ET Primary Endpoint of Safety Met Across all Study GroupsStatistical Significance Met for Secondary Endpoint Composite Alzheimer's Disease Score (CADS) for Lomecel-B™ Low-Dose and for the Pooled Lomecel-B™ Treatment Group Relative to PlaceboOther Doses Demonstrated Numerical Slowing/Prevention of Disease Worsening Relative to Placebo Additional Biomarker Data Expected to be Announced in the Coming Weeks MIAMI, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related cond

ELPIS II Study Exceeds 50% Enrollment Threshold for Phase 2 Trial of Lomecel-B™ in HLHS Top Line Results for CLEAR MIND Alzheimer's disease Phase 2a Trial Anticipated by October 2023 Company Strengthens Leadership Team and Board of Directors with Distinguished New Additions Company to Hold Conference Call and Webcast Today, August 11, 2023 at 8am Eastern Time MIAMI, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today its results for the quarter ended June 30, 2023 and provided a corporate update. "During our second quarter and in

MIAMI, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today that it will report its second quarter 2023 financial results prior to the market open on Friday, August 11, 2023. The Company will host a conference call and webcast that day to discuss the results, provide an update on its clinical programs and corporate activities. A question-and-answer session will follow the prepared remarks. TitleLongeveron Second Quarter 2023 Financial ResultsDateFriday, August 11, 2023Time8:00 AM Eastern TimeConference Call D

-- New long-term survival data disclosed from ELPIS I trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome; Data reinforce potential mortality benefit -- -- First patient dosed in Phase 2 clinical trial of Lomecel-BTM for Aging-Related Frailty in Japan -- -- Conference call scheduled for 8:30 a.m. ET today -- MIAMI, May 12, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today provided a business update and reported its financial results for the first quarter ended March 31, 2023. "In 2023, we have continued to make steady progress advanc

MIAMI, May 08, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that the Company will release its first quarter 2023 financial results on Friday, May 12, 2023 before the open of the U.S. financial markets. Management will host a conference call to discuss the Company's financial results and provide a corporate update on the same day at 8:30 a.m. ET. Dial-in NumberU.S. Dial-in Number: 833-470-1428Canada Dial-in Number: 833-950-0062All Other Locations Dial-in Number: 929-526-1599Access code: 138185 U.S. Replay Dial-in Number: 866-813-9

MIAMI, March 06, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that the Company will release its fourth quarter and full year 2022 financial results on Friday, March 10, 2023 before the open of the U.S. financial markets. Management will host a conference call to discusss the Company's financial results and provide a corporate update on the same day at 8:30 a.m. ET. Dial-in NumberU.S. Dial-in Number: 833 470 1428Canada Dial-in Number: 833 950 0062Global Dial-In NumbersAccess code: 621807 U.S. Replay Dial-in Number: 866 813 9403All Other L

-- Achieved key clinical and regulatory milestones across clinical pipeline, including the completion of enrollment in Longeveron's Phase 2a trial for Alzheimer's Disease -- -- Conference call scheduled for 8:30 a.m. ET today -- MIAMI, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today provided a business update and reported its financial results for the third quarter ended September 30, 2022. "This quarter, we continued to make robust progress across our 3 clinical programs," said Chris Min, M.D., Ph.D., Interim Chief Execut

MIAMI, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that the Company will release its third quarter 2022 financial results on Monday, November 14, 2022 before the open of the U.S. financial markets. Management will host a conference call to discuss the Company's financial results and provide a corporate update on the same day at 8:30 a.m. EST. Dial-in NumberU.S. Dial-in Number: 844-200-6205Canada Dial-in Number: 833-950-0062All Other Locations Dial-in Number: 929-526-1599Access code: 982246 U.S. Replay Dial-in Number: 866-813-94

MIAMI, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its second quarter 2022 financial results on Friday, August 12, 2022 before the open of the U.S. financial markets. Management will host a conference call to discuss the Company's financial results and provide a corporate update on the same day at 8:30 a.m. EST. Dial-in NumberU.S. Dial-in Number: 844-200-6205Canada Dial-in Number: 833-950-0062All Other Locations Dial-in Number: 929-526-1599Access code: 788626 U.S. Repl

MIAMI, May 13, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today provided a business update and reported its financial results for the first quarter ended March 31, 2022. First Quarter Business Updates: Lomecel-B for Alzheimer's Disease: In January 2022, we initiated enrollment in a 48-patient, 4-arm, parallel design, randomized (1:1:1:1) Phase 2a clinical trial of Lomecel-B infusion in patients with mild Alzheimer's disease. The Phase 2a study is intended to evaluate the safety of single and multiple infusions of t

MIAMI, May 09, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its first quarter 2022 financial results on Friday, May 13, 2022 before the open of the U.S. financial markets. Management will host a conference call to discuss the Company's financial results and provide a corporate update on the same day at 8:30 a.m. EST. Dial-in NumberU.S. Dial-in Number: 844-200-6205Canada Dial-in Number: 833-950-0062All Other Locations Dial-in Number: 929-526-1599Access code: 309564 U.S. Replay Di

MIAMI, March 07, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its fourth quarter and year-end 2021 financial results on Friday, March 11, 2022 before the open of U.S. financial markets. Management will host a conference call to discuss the Company's financial results and provide a corporate update on the same day at 8:30 a.m. EST. Dial-in NumberU.S. Dial-in Number: 844-200-6205Canada Dial-in Number: 833-950-0062All Other Locations Dial-in Number: 929-526-1599Conference ID: 770734

MIAMI, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its third quarter 2021 financial results on Friday, November 12, 2021 before the open of US markets. Management will host a conference call on the same day at 8:30 a.m. ET. The conference call will be available via telephone by dialing toll free 1-844-200-6205 for U.S. callers; 1-646-904-5544 for local callers; or +1 929-526-1599 for international callers and using entry code 397367. An audio replay of the of the call w

-- Study meets one of the two analyses of primary efficacy endpoint: statistically significant dose-response in six-minute walk test (6MWT) at Day 180 -- Longeveron to hold conference call today at 8:00 AM EDT MIAMI, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced results from the Company's Phase 2b trial titled: A Phase 2b, Randomized, Blinded and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Lomecel-B Infusion in Patients With Aging Frailty (the "Phase 2b trial"). Lomecel-B is a pro

MIAMI, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its second quarter 2021 financial results on Friday, August 13, 2021 before the open of US markets. Management will host a conference call on the same day at 8:00 AM. The conference call will be available via telephone by dialing toll free 1-844-200-6205 for U.S. callers; 1-646-904-5544 for local callers; or + 44 208-068-2558 for international callers and using entry code 874656. An audio replay of the of the call will